The legacy of the blue pill offers a complex case study for stakeholders eyeing pharma. While first sales were astounding, current patent expiry and the rise of generic versions have severely affected profitability. In https://aoifezopb900938.tinyblogging.com/the-blue-pill-and-the-pharmaceutical-industry-a-risky-investment-85178756